Literature DB >> 20192976

Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study.

Panagiota Georgiadou1, Efstathios K Iliodromitis, Fotios Kolokathis, Christos Varounis, Vassilis Gizas, Manolis Mavroidis, Yassemi Capetanaki, Harisios Boudoulas, Dimitrios T Kremastinos.   

Abstract

OBJECTIVES: Osteopontin (OPN) is a glycoprotein, which may play a major role in the regulation of biological phenomena. Increased levels of OPN have been linked to the presence and to the severity of atherosclerosis. This study was undertaken to assess the prognostic significance of plasma OPN levels in patients with stable ischaemic heart disease (IHD).
METHODS: In 101 patients with stable IHD and angiographically documented significant coronary artery stenosis, plasma OPN levels were measured at baseline (time of coronary arteriography). Patients were prospectively followed for a median time of 3 years (minimum 2.25, maximum 3.9 years). The primary study endpoint was the composite of cardiovascular death, non-fatal myocardial infarction, need for revascularization and hospitalization for cardiovascular reasons.
RESULTS: Baseline lnOPN levels were directly related to age (r = 0.27, P < 0.001) and inversely to left ventricular ejection fraction (r = -0.32, P < 0.01). Left ventricular ejection fraction was an independent predictor of plasma OPN levels after adjustment for age and gender (beta = -0.013, P = 0.02). Median OPN value was 55 ng mL(-1). In the univariate Cox-regression analysis, OPN levels > 55 ng mL(-1) (n = 50) were significantly related to adverse cardiac outcome (HR = 2.40, 95% CI: 1.11-5.23, P = 0.027). In multivariate model, OPN levels > 55 ng mL(-1) remained statistically significant independent predictor of adverse outcome after adjustment for age, gender, left ventricular ejection fraction and the number of diseased coronary arteries (HR = 2.88, 95% CI: 1.09-7.58, P = 0.032).
CONCLUSION: OPN may provide significant prognostic information independent of other traditional prognostic markers in patients with stable IHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192976     DOI: 10.1111/j.1365-2362.2010.02257.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

Review 1.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Urinary Osteopontin Predicts Incident Chronic Kidney Disease, while Plasma Osteopontin Predicts Cardiovascular Death in Elderly Men.

Authors:  Tobias Feldreich; Axel C Carlsson; Johanna Helmersson-Karlqvist; Ulf Risérus; Anders Larsson; Lars Lind; Johan Ärnlöv
Journal:  Cardiorenal Med       Date:  2017-05-25       Impact factor: 2.041

3.  Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.

Authors:  Annette M Lim; Danny Rischin; Richard Fisher; Hongbin Cao; Kathleen Kwok; Daniel Truong; Grant A McArthur; Richard J Young; Amato Giaccia; Lester Peters; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2011-11-17       Impact factor: 12.531

Review 4.  Integrating the myocardial matrix into heart failure recognition and management.

Authors:  Francis G Spinale; Michael R Zile
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

5.  Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAs.

Authors:  Helene Skjøt-Arkil; Rikke E Clausen; Lars M Rasmussen; Wanchun Wang; Yaguo Wang; Qinlong Zheng; Hans Mickley; Lotte Saaby; Axel C P Diederichsen; Jess Lambrechtsen; Fernando J Martinez; Cory M Hogaboam; Meilan Han; Martin R Larsen; Arkadiusz Nawrocki; Ben Vainer; Dorrit Krustrup; Marina Bjørling-Poulsen; Morten A Karsdal; Diana J Leeming
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

6.  Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling.

Authors:  Norifumi Takeda; Ichiro Manabe
Journal:  Int J Inflam       Date:  2011-09-18

Review 7.  Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era.

Authors:  Umberto Barbero; Fabrizio D'Ascenzo; Freek Nijhoff; Claudio Moretti; Giuseppe Biondi-Zoccai; Marco Mennuni; Davide Capodanno; Marco Lococo; Michael J Lipinski; Fiorenzo Gaita
Journal:  Scientifica (Cairo)       Date:  2016-04-27

Review 8.  Positron emission tomography imaging of coronary atherosclerosis.

Authors:  Alastair J Moss; Philip D Adamson; David E Newby; Marc R Dweck
Journal:  Future Cardiol       Date:  2016-07

9.  Osteopontin in relation to Prognosis following Coronary Artery Bypass Graft Surgery.

Authors:  Eftihia Sbarouni; Panagiota Georgiadou; Sofia Chatzikyriakou; Antonis Analitis; Antigoni Chaidaroglou; Demitris Degiannis; Vassilis Voudris
Journal:  Dis Markers       Date:  2016-08-14       Impact factor: 3.434

10.  Novel cardiac-specific biomarkers and the cardiovascular continuum.

Authors:  Efstathios Vassiliadis; Natasha Barascuk; Athanasios Didangelos; Morten A Karsdal
Journal:  Biomark Insights       Date:  2012-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.